Melissa L. Kirkwood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Melissa L. Kirkwood has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin M. Jackson
University of Pennsylvania
3 shared publications - Edward Y. Woo
Division of Vascular Surgery and Endovascular Therapy, University of Pennsylvania Health System, Philadelphia, Pa
3 shared publications - Grace J. Wang
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pa
3 shared publications - Ronald M. Fairman
Division of Vascular Surgery and Endovascular Therapy, University of Pennsylvania Health System, Philadelphia, Pa
3 shared publications Benjamin M. Jackson
Division of Vascular Surgery and Endovascular Therapy, University of Pennsylvania Health System, Philadelphia, PA, USA
2 shared publicationsEdward Y. Woo
Division of Vascular Surgery and Endovascular Therapy, University of Pennsylvania Health System, Philadelphia, PA, USA
2 shared publications
Latest Publications
- 1 June 2012
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 55 (6) , 50S
PS88. Repetition Using a High-Fidelity Endovascular Simulator Improves Technical Performance with a High Retention Rate
- 1 June 2012
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 55 (6) , 50S
PS88. Repetition Using a High-Fidelity Endovascular Simulator Improves Technical Performance with a High Retention Rate
- 12 September 2011
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 54 (6) , 1588-1591
Simultaneous thoracic endovascular aortic repair and endovascular aortic repair is feasible with minimal morbidity and mortality
- 12 September 2011
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 54 (6) , 1588-1591
Simultaneous thoracic endovascular aortic repair and endovascular aortic repair is feasible with minimal morbidity and mortality
- 28 March 2011
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 45 (4) , 329-334
Lower Limb Revascularization for PAD Using a Heparin-Coated PTFE Conduit
Objective: To assess the patency of the PROPATEN Graft in lower extremity bypasses. Methods: We retrospectively reviewed all lower extremity bypasses with the PROPATEN Graft from 2007-2009 at a single institution. There were 68 implants—56% male; mean age 69. Comorbidities included hypertension (HTN; 81%), hyperlipidemia (72%), coronary artery disease (CAD; 74%), and smoking (59%). Most patients were Rutherford category 4 or higher. A total of 34% of patients had only 1 runoff vessel; 10% of patients required a complex concomitant procedure with sequential extremity revascularization. Statistics were via Kaplan Meier. Results: Mean follow-up was10.4 ± 8.0 months (0-30). Patency was excellent in all positions. Primary patency for all patients was 94.0% and 86.0% at 30 days and 18 months, respectively. Limb salvage at 30 days was 95%, and at 18 months was 90%. No patients developed HIT. Ten patients lost graft patency. These patients had severe Peripheral Vascular Disease (PVD), with rest pain or tissue loss, poor runoff (no runoff or single vessel runoff), compromised inflow, and restored competitive flow. Fifty percent of the failed grafts were in the infrapopliteal position. Endovascular intervention and graft thrombectomy to restore patency was attempted in 2 patients and was unsuccessful. Conclusion: The GORE PROPATEN Vascular Graft demonstrates excellent patency in all arterial positions and may be the conduit of choice for all prosthetic bypasses.
- 28 March 2011
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 45 (4) , 329-334
Lower Limb Revascularization for PAD Using a Heparin-Coated PTFE Conduit
Objective: To assess the patency of the PROPATEN Graft in lower extremity bypasses. Methods: We retrospectively reviewed all lower extremity bypasses with the PROPATEN Graft from 2007-2009 at a single institution. There were 68 implants—56% male; mean age 69. Comorbidities included hypertension (HTN; 81%), hyperlipidemia (72%), coronary artery disease (CAD; 74%), and smoking (59%). Most patients were Rutherford category 4 or higher. A total of 34% of patients had only 1 runoff vessel; 10% of patients required a complex concomitant procedure with sequential extremity revascularization. Statistics were via Kaplan Meier. Results: Mean follow-up was10.4 ± 8.0 months (0-30). Patency was excellent in all positions. Primary patency for all patients was 94.0% and 86.0% at 30 days and 18 months, respectively. Limb salvage at 30 days was 95%, and at 18 months was 90%. No patients developed HIT. Ten patients lost graft patency. These patients had severe Peripheral Vascular Disease (PVD), with rest pain or tissue loss, poor runoff (no runoff or single vessel runoff), compromised inflow, and restored competitive flow. Fifty percent of the failed grafts were in the infrapopliteal position. Endovascular intervention and graft thrombectomy to restore patency was attempted in 2 patients and was unsuccessful. Conclusion: The GORE PROPATEN Vascular Graft demonstrates excellent patency in all arterial positions and may be the conduit of choice for all prosthetic bypasses.
- 28 February 2011
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 53 (2) , 269-273
Aneurysmal iliac arteries do not portend future iliac aneurysmal enlargement after endovascular aneurysm repair for abdominal aortic aneurysm
- 28 February 2011
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 53 (2) , 269-273
Aneurysmal iliac arteries do not portend future iliac aneurysmal enlargement after endovascular aneurysm repair for abdominal aortic aneurysm
- 2 June 2010
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 44 (6) , 440-445
Thoracic Aortic Endograft Explant: A Single-Center Experience
Objectives: We report our experience following thoracic aortic endovascular repair (TEVAR) explant. Methods: A total of 500 TEVARs were performed from 1999 to 2009, with 4 requiring explant. Chart review was performed to identify the indications of explant, operative technique, and perioperative morbidity and mortality. Results: Indications of graft removal included device maldeployment, type I endoleak, aortoenteric fistula, and retrograde type A dissection necessitating aortic root replacement. Reconstruction was achieved with aortic homograft, Dacron, or explant of the proximal component with incorporation of the distal stent into the suture line. Mean follow-up was 13 months (0-50 months). Paraplegia and perioperative death occurred in 1 patient who underwent intraoperative conversion to open repair. There were no other major complications, and graft removal was achieved in all patients. Conclusions: Although rare, familiarity with TEVAR explant is imperative as it is increasingly performed for broader indications. Our limited data suggest that explant can be performed successfully albeit with morbidity.
- 2 June 2010
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 44 (6) , 440-445
Thoracic Aortic Endograft Explant: A Single-Center Experience
Objectives: We report our experience following thoracic aortic endovascular repair (TEVAR) explant. Methods: A total of 500 TEVARs were performed from 1999 to 2009, with 4 requiring explant. Chart review was performed to identify the indications of explant, operative technique, and perioperative morbidity and mortality. Results: Indications of graft removal included device maldeployment, type I endoleak, aortoenteric fistula, and retrograde type A dissection necessitating aortic root replacement. Reconstruction was achieved with aortic homograft, Dacron, or explant of the proximal component with incorporation of the distal stent into the suture line. Mean follow-up was 13 months (0-50 months). Paraplegia and perioperative death occurred in 1 patient who underwent intraoperative conversion to open repair. There were no other major complications, and graft removal was achieved in all patients. Conclusions: Although rare, familiarity with TEVAR explant is imperative as it is increasingly performed for broader indications. Our limited data suggest that explant can be performed successfully albeit with morbidity.